Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.1.154 - phosphatidylinositol-4-phosphate 3-kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Lung Injury
Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury.
Arthritis, Rheumatoid
Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase ? inhibitor for the treatment of inflammatory diseases.
Novel phosphoinositide 3-kinase ?,? inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
Asthma
Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002.
Consensus model for identification of novel PI3K inhibitors in large chemical library.
Phosphoinositide 3-kinase {delta} inhibitor suppresses IL-17 expression in a murine asthma model.
PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge.
Autoimmune Diseases
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
PI3K inhibitors as potential therapeutics for autoimmune disease.
Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
Breast Neoplasms
Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer.
Class II phosphoinositide 3-kinase C2? regulates a novel signaling pathway involved in breast cancer progression.
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay.
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
Burkitt Lymphoma
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Carcinogenesis
Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif.
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay.
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis.
The recent progress and therapy in endometriosis-associated ovarian cancer.
[Involvement of phosphoinositide 3-kinases and phosphoinositide phosphatases in immune responses, glucose metabolism and tumorigenesis]
Carcinoma
The recent progress and therapy in endometriosis-associated ovarian cancer.
Carcinoma, Hepatocellular
A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.
beta-estradiol stimulation of DNA synthesis requires different PKC isoforms in HepG2 and MCF7 cells.
Carcinoma, Squamous Cell
Phosphoinositide 3-Kinase C2beta Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent Mechanisms.
Cardiovascular Diseases
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Consensus model for identification of novel PI3K inhibitors in large chemical library.
PI3K Inhibitors in Cardiovascular Disease.
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Colonic Neoplasms
Down-regulation of p110? expression increases chemosensitivity of colon cancer cell lines to oxaliplatin.
Colorectal Neoplasms
Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay.
PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin.
Diabetes Mellitus, Type 2
Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese population.
Insulin-feedback via PI3K-C2{alpha} activated PKB{alpha}/Akt1 is required for glucose-stimulated insulin secretion.
Diabetic Cardiomyopathies
Phosphoinositide 3-kinases and Diabetic Cardiomyopathy.
Diphtheria
PI3KC2?, a class II PI3K, is required for dynamin-independent internalization pathways.
Encephalomyelitis
PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
Encephalomyelitis, Autoimmune, Experimental
PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
Epilepsy
Phosphoinositide 3-Kinases Upregulate System xc(-) via Eukaryotic Initiation Factor 2? and Activating Transcription Factor 4?-?A Pathway Active in Glioblastomas and Epilepsy.
Fibrosarcoma
3-Methyladenine suppresses cell migration and invasion of HT1080 fibrosarcoma cells through inhibiting phosphoinositide 3-kinases independently of autophagy inhibition.
Glioblastoma
Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay.
Phosphoinositide 3-Kinases Upregulate System xc(-) via Eukaryotic Initiation Factor 2? and Activating Transcription Factor 4?-?A Pathway Active in Glioblastomas and Epilepsy.
Hepatitis C
A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.
Hypotension
Class II phosphoinositide 3-kinase alpha-isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle.
Immune System Diseases
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Infections
iTRAQ-based proteomic profile analysis of ISKNV-infected CPB cells with emphasizing on glucose metabolism, apoptosis and autophagy pathways.
Insulin Resistance
Discovery of phosphoinositide 3-kinases (PI3K) p110? isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.
Insulinoma
Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells.
Leukemia
Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells.
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Leukemia, Lymphocytic, Chronic, B-Cell
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Leukemia, Myeloid, Acute
Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells.
Leukemia, Promyelocytic, Acute
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Lymphadenopathy
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase ? syndrome 2: A cohort study.
Lymphoma
Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.
Lymphoma, Follicular
miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.
Multiple Myeloma
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Multiple Sclerosis
PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
Myopathies, Structural, Congenital
Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy.
Neoplasms
A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product.
A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM.
A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity.
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
Characterisation of the PTEN inhibitor VO-OHpic.
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.
Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.
Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells.
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Class II phosphoinositide 3-kinase C2? regulates a novel signaling pathway involved in breast cancer progression.
Consensus model for identification of novel PI3K inhibitors in large chemical library.
Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.
Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration.
Disease-related mutations in PI3K? disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors.
Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
Downregulation of class II phosphoinositide 3-kinase PI3K-C2? delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Extended treatment with selective PI 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength.
Genetic and epigenetic regulation of phosphoinositide 3-kinase Isoforms.
Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair.
Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay.
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
Multi-kinase inhibitors, AURKs and cancer.
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Phosphoinositide 3-Kinase C2beta Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent Mechanisms.
Phosphoinositide 3-kinases as drug targets in cancer.
Phytochemicals and Gastrointestinal Cancer: Cellular Mechanisms and Effects to Change Cancer Progression.
PI3K at the crossroads of tumor angiogenesis signaling pathways.
PI3K/AKT signaling pathway and cancer: an updated review.
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.
Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations.
Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors.
Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Signal Transduction Pathways as Therapeutic Targets. 25-28 January 2004, Luxembourg.
Stromal cell protein kinase C-? inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.
Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts.
Targeting PI3K in neuroblastoma.
The Essential Role of Phosphoinositide 3-Kinases (PI3Ks) in Regulating Pro-Inflammatory Responses and the Progression of Cancer.
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
The relation between PI3K/AKT signalling pathway and cancer.
The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion.
Theoretical studies on the selectivity mechanisms of PI3K? inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
TSC1 Activates TGF-?-Smad2/3 Signaling in Growth Arrest and Epithelial-to-Mesenchymal Transition.
Uncovering the PI3Ksome: phosphoinositide 3-kinases and counteracting PTEN form a signaling complex with intrinsic regulatory properties.
Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression.
Neuroblastoma
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis.
Targeting PI3K in neuroblastoma.
Primary Immunodeficiency Diseases
Conformational disruption of PI3K? regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Prostatic Neoplasms
Downregulation of class II phosphoinositide 3-kinase PI3K-C2? delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay.
Novel roles for class II Phosphoinositide 3-Kinase C2? in signalling pathways involved in prostate cancer cell invasion.
Psoriasis
Hypoxia-inducible factor-1: A potential pharmacological target to manage psoriasis.
Sarcoma
The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy.
Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Sepsis
In Search of a Cure for Sepsis: Taming the Monster in Critical Care Medicine.
Squamous Cell Carcinoma of Head and Neck
The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Thrombosis
Membrane grease eases platelet maturation.
Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics.
Resistance to thromboembolism in PI3Kgamma-deficient mice.
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
Uterine Cervical Neoplasms
Downregulation of class II phosphoinositide 3-kinase PI3K-C2? delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Whooping Cough
The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha.